The safety and efficacy of vosaroxin in patients with first relapsed or refractory acute myeloid leukemia - a critical review

References

• Juliusson G, Antunovic P, Derolf A, et al. Age and acute myeloid leukemia: real world data on decision to treat and outcomes from the Swedish acute leukemia registry. Blood. 2009;113:4179–4187.
   PubMed Web of Science ®Google Scholar
• Breems DA, Van Putten WL, Huijgens PC, et al. Prognostic index for adult patients with acute myeloid leukemia in first relapse. J Clin Oncol. 2005;23:1969–1978.
   PubMed Web of Science ®Google Scholar
• Pemmaraju N, Kantarjian H, Garcia-Manero G, et al. Improving outcomes for patients with acute myeloid leukemia in first relapse: a single center experience. Am J Hematol. 2015;90:27–30.
   PubMed Web of Science ®Google Scholar
• Burnett AK, Goldstone A, Hills RK, et al. Curability of patients with acute myeloid leukemia who did not undergo transplantation in first remission. J Clini Oncol. 2013;31:1293–1301.
   PubMed Web of Science ®Google Scholar
• National Comprehensive Cancer Network. Acute myeloid leukemia (Version 1.2015). [cited 2016 Mar 1]. Available from: https://www.nccn.org/professionals/physician_gls/PDF/aml.pdf.
   Google Scholar
• Roboz GJ, Rosenblat T, Arellano M, et al. International randomized phase III study of elacytarabine versus investigator choice in patients with relapsed/refractory acute myeloid leukemia. J Clin Oncol. 2014;32:1919–1926.
   PubMed Web of Science ®Google Scholar
• Kantarjian H, O’Brien S, Cortes J, et al. Results of intensive chemotherapy in 998 patients age 65 years or older with acute myeloid leukemia or high-risk myelodysplastic syndrome: predictive prognostic models for outcome. Cancer. 2006;106:1090–1098.
   PubMed Web of Science ®Google Scholar
• Walter RB, Estey EH. Management of older or unfit patients with acute myeloid leukemia. Leukemia. 2015;29:770–775.
   PubMed Web of Science ®Google Scholar
• Sorror ML, Storb RF, Sandmaier BM, et al. Comorbidity-age index: a clinical measure of biologic age before allogeneic hematopoietic cell transplantation. J Clin Oncol. 2014;32:3249–3256.
   PubMed Web of Science ®Google Scholar
• Hawtin RE, Stockett DE, Byl JA, et al. Voreloxin is an anticancer quinolone derivative that intercalates DNA and poisons topoisomerase II. Plos one. 2010;5:e10186.
   PubMed Web of Science ®Google Scholar
• Hawtin RE, Stockett DE, Wong OK, et al. Homologous recombination repair is essential for repair of vosaroxin-induced DNA double-strand breaks. Oncotarget. 2010;1:606–619.
   PubMed Web of Science ®Google Scholar
• Mjos KD, Cawthray JF, Jamieson G, et al. Iron(III)-binding of the anticancer agents doxorubicin and vosaroxin. Dalton Trans. ( Cambridge, England: 2003). 2015;44:2348–2358.
   PubMed Web of Science ®Google Scholar
• Hoch U, Lynch J, Sato Y, et al. Voreloxin, formerly SNS-595, has potent activity against a broad panel of cancer cell lines and in vivo tumor models. Cancer Chemother Pharmacol. 2009;64:53–65.
   PubMed Web of Science ®Google Scholar
• Evanchik MJ, Allen D, Yoburn JC, et al. Metabolism of (+)-1,4-dihydro-7-(trans-3-methoxy-4-methylamino-1-pyrrolidinyl)-4-oxo-1-(2-thiaz olyl)-1,8-naphthyridine-3-carboxylic acid (voreloxin; formerly SNS-595), a novel replication-dependent DNA-damaging agent. Drug Metab Dispos. 2009;37:594–601.
   PubMed Web of Science ®Google Scholar
• Walsby EJ, Coles SJ, Knapper S, et al. The topoisomerase II inhibitor voreloxin causes cell cycle arrest and apoptosis in myeloid leukemia cells and acts in synergy with cytarabine. Haematologica. 2011;96:393–399.
   PubMed Web of Science ®Google Scholar
• Scatena CD, Kumer JL, Arbitrario JP, et al. Voreloxin, a first-in-class anticancer quinolone derivative, acts synergistically with cytarabine in vitro and induces bone marrow aplasia in vivo. Cancer Chemother Pharmacol. 2010;66:881–888.
   PubMed Web of Science ®Google Scholar
• Advani RH, Hurwitz HI, Gordon MS, et al. Voreloxin, a first-in-class anticancer quinolone derivative, in relapsed/refractory solid tumors: a report on two dosing schedules. Clin Cancer Res. 2010;16:2167–2175.
   PubMed Web of Science ®Google Scholar
• Lancet JE, Roboz GJ, Cripe LD, et al. A phase 1b/2 study of vosaroxin in combination with cytarabine in patients with relapsed or refractory acute myeloid leukemia. Haematologica. 2015;100:231–237.
   PubMed Web of Science ®Google Scholar
• Ravandi F, Ritchie EK, Sayar H, et al. Vosaroxin plus cytarabine versus placebo plus cytarabine in patients with first relapsed or refractory acute myeloid leukaemia (VALOR): a randomised, controlled, double-blind, multinational, phase 3 study. Lancet Oncol. 2015;16:1025–1036.
   PubMed Web of Science ®Google Scholar
• Stuart RK, Cripe LD, Maris MB, et al. REVEAL-1, a phase 2 dose regimen optimization study of vosaroxin in older poor-risk patients with previously untreated acute myeloid leukaemia. Br J Haematol. 2015;168:796–805.
   PubMed Web of Science ®Google Scholar
• Dennis M, Russell N, Hills RK, et al. Vosaroxin and vosaroxin plus low-dose Ara-C (LDAC) vs low-dose Ara-C alone in older patients with acute myeloid leukemia. Blood. 2015;125:2923–2932.
   PubMed Web of Science ®Google Scholar
• Lancet JE, Ravandi F, Ricklis RM, et al. A phase Ib study of vosaroxin, an anticancer quinolone derivative, in patients with relapsed or refractory acute leukemia. Leukemia. 2011;25:1808–1814.
   PubMed Web of Science ®Google Scholar
• Burnett AK, Hills RK, Hunter A, et al. The addition of arsenic trioxide to low-dose Ara-C in older patients with AML does not improve outcome. Leukemia. 2011;25:1122–1127.
   PubMed Web of Science ®Google Scholar
• Burnett AK, Hills RK, Hunter AE, et al. The addition of gemtuzumab ozogamicin to low-dose Ara-C improves remission rate but does not significantly prolong survival in older patients with acute myeloid leukaemia: results from the LRF AML14 and NCRI AML16 pick-a-winner comparison. Leukemia. 2013;27:75–81.
   PubMed Web of Science ®Google Scholar
• Dohner H, Lubbert M, Fiedler W, et al. Randomized, phase 2 trial of low-dose cytarabine with or without volasertib in AML patients not suitable for induction therapy. Blood. 2014;124:1426–1433.
   PubMed Web of Science ®Google Scholar
• Daver N, Kantarjian HM, Garcia-Manero G, et al. Phase I/II study of vosaroxin and decitabine in newly diagnosed older patients (pts) with acute myeloid leukemia (AML) and high risk myelodysplastic syndrome (MDS). Blood. 2015;126:461–461.
   Google Scholar
• Ravandi F. Relapsed acute myeloid leukemia: why is there no standard of care? Best Pract Res Clin Gastroenterol. 2013;26:253–259.
   Web of Science ®Google Scholar
• Sarkozy C, Gardin C, Gachard N, et al. Outcome of older patients with acute myeloid leukemia in first relapse. Am J Hematol. 2013;88:758–764.
   PubMed Web of Science ®Google Scholar
• Fenaux P, Mufti GJ, Hellstrom-Lindberg E, et al. Azacitidine prolongs overall survival compared with conventional care regimens in elderly patients with low bone marrow blast count acute myeloid leukemia. J Clin Oncol. 2010;28:562–569.
   PubMed Web of Science ®Google Scholar
• Kantarjian HM, Thomas XG, Dmoszynska A, et al. Multicenter, randomized, open-label, phase III trial of decitabine versus patient choice, with physician advice, of either supportive care or low-dose cytarabine for the treatment of older patients with newly diagnosed acute myeloid leukemia. J Clin Oncol. 2012;30:2670–2677.
   PubMed Web of Science ®Google Scholar
• Dombret H, Seymour JF, Butrym A, et al. International phase 3 study of azacitidine vs conventional care regimens in older patients with newly diagnosed AML with >30% blasts. Blood. 2015;126:291–299.
   PubMed Web of Science ®Google Scholar
• Patel JP, Gonen M, Figueroa ME, et al. Prognostic relevance of integrated genetic profiling in acute myeloid leukemia. N Engl J Med. 2012;366:1079–1089.
   PubMed Web of Science ®Google Scholar
• Cancer Genome Atlas Research Network. Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia. N Engl J Med. 2013;368:2059–2074.
   PubMed Web of Science ®Google Scholar
• Kadia TM, Ravandi F, Cortes J, et al. Toward individualized therapy in acute myeloid Leukemia: a contemporary review. JAMA Oncol. 2015;1:820–828.
   PubMed Web of Science ®Google Scholar